---
document_datetime: 2026-01-07 11:46:50
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/gazyvaro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: gazyvaro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.2027565
conversion_datetime: 2026-01-10 11:12:30.578406
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Gazyvaro

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | A. ADMINISTRATIVE CHANGES - A.7 | 20/11/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000313543                     | Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |             |                                                                                |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000244907 | C.I.6 Change(s) to therapeutic indication(s) - C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted Extension of indication to include treatment of adult patients with active lupus nephritis who are receiving standard therapy for GAZYVARO, based on results from study Regency (CA41705). This is an ongoing, Phase III, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of obinutuzumab administered at standard infusion rates in patients with ISN/RPS 2003 Class III or IV lupus nephritis treated with standard-of-care therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 11 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the | 16/10/2025 | 04/12/2025 | SmPC and PL | Please refer to Scientific Discussion 'Gazyvaro-H-C- 002799-II- VR/0000244907' |

<div style=\"page-break-after: always\"></div>

|                                       | representatives in the Package Leaflet.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| Variation type IA / EMA/VR/0000303710 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.b Deletion of a test procedure for the active substance or a starting material/reagent/ intermediate, if an alternative test procedure is already authorised. - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.b Deletion of a test procedure if an alternative method is already authorised - Accepted | 07/10/2025 | N/A        |             |
| Variation type II / EMA/VR/0000257509 | This was an application for a group of variations. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.3 After dilution                                                                                                                                                                                           | 22/05/2025 | 04/12/2025 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

| or reconstitution (supported by real time data) - Accepted   |
|--------------------------------------------------------------|